行情

SBPH

SBPH

Spring Bk Pharms
NASDAQ

实时行情|Nasdaq Last Sale

3.380
-0.020
-0.59%
已收盘, 16:00 12/10 EST
开盘
3.330
昨收
3.400
最高
3.570
最低
3.330
成交量
23.89万
成交额
--
52周最高
11.90
52周最低
2.750
市值
5,569.00万
市盈率(TTM)
-2.5173
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBPH 新闻

  • Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
  • GlobeNewswire.1天前
  • 报告:秘鲁2019年三季度倒闭公司数量同比增五成
  • 中国新闻网.12/03 10:16
  • 英国保守党支持率较工党的领先优势扩大至12个百分点
  • 新浪财经综合.12/03 10:15
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.12/03 09:56

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
-0.29%

热门股票

名称
价格
涨跌幅

SBPH 简况

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
展开

Webull提供Spring Bank Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。